These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18705680)

  • 1. Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab.
    Yoon YH; Kim JG; Chung H; Lee SY
    Acta Ophthalmol; 2009 Sep; 87(6):685-7. PubMed ID: 18705680
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.
    Krebs I; Lie S; Stolba U; Zeiler F; Felke S; Binder S
    Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab.
    Lucas RS; McKee HD; Lee LR
    Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
    [No Abstract]   [Full Text] [Related]  

  • 5. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Gelisken F; Ziemssen F; Voelker M; Bartz-Schmidt KU
    Acta Ophthalmol Scand; 2006 Dec; 84(6):833-4. PubMed ID: 17083554
    [No Abstract]   [Full Text] [Related]  

  • 6. Controversies in the treatment of wet age-related macular degeneration.
    Moreno SF; Paloma JB
    Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
    Jonas JB; Tao Y; Rensch F
    Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration.
    Guthoff R; Guthoff T; Meigen T; Goebel W
    Retina; 2011 Jan; 31(1):36-40. PubMed ID: 20921929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
    Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
    Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case of anterior uveitis after intravitreal injection of bevacizumab.
    Pieramici DJ; Avery RL; Castellarin AA; Nasir MA; Rabena M
    Retina; 2006 Sep; 26(7):841-2. PubMed ID: 16963867
    [No Abstract]   [Full Text] [Related]  

  • 14. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease.
    Wong LJ; Desai RU; Jain A; Feliciano D; Moshfeghi DM; Sanislo SR; Blumenkranz MS
    Retina; 2008 Oct; 28(8):1151-8. PubMed ID: 18685542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration.
    Meyer CH; Mennel S; Schmidt JC; Kroll P
    Br J Ophthalmol; 2006 Sep; 90(9):1207-8. PubMed ID: 16929069
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab local complications.
    Gordon-Angelozzi M; Velez-Montoya R; Fromow-Guerra J; García-Aguirre G; Guerrero-Naranjo JL; Quiroz-Mercado H; Morales-Cantón V
    Ophthalmology; 2009 Nov; 116(11):2264.e1-3. PubMed ID: 19883862
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
    Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
    Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
    Ronan SM; Yoganathan P; Chien FY; Corcóstegui IA; Blumenkranz MS; Deramo VA; Elner SG; Fastenberg DA; Johnson MW; López M; Mateo C; Moshfeghi DM; Navarro R; Rosenblatt BJ; Sanislo SR; Saxe SJ; Zacks DN
    Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.